Phytocannabinoids — especially CBD — show promise for psoriasis by reducing oxidative stress and pro-inflammatory cytokines, but clinical evidence in human psoriasis patients is still minimal.
Read this if you have psoriasis and are curious about CBD topicals or other cannabinoid products — the science behind the idea is real, but proven clinical benefit hasn't been established yet.
What the researchers found
Psoriasis is a chronic autoimmune skin condition where the immune system attacks healthy skin cells, causing red, scaly patches that can be painful and disfiguring. It affects about 2-3% of the global population and has no cure — only management. This review examines whether cannabinoids from the cannabis plant could offer a new treatment pathway.
The biological rationale is sound. Psoriasis is driven by two intertwined problems: oxidative stress (an imbalance between damaging free radicals and the body's antioxidant defenses) and chronic inflammation (overactive immune cells pumping out pro-inflammatory cytokines). Phytocannabinoids, particularly CBD, have been shown to address both: they can boost antioxidant systems and suppress inflammatory cytokine production.
CBD interacts with several receptor systems in the skin, including CB1, CB2, TRPV1, and PPARγ — all of which are involved in skin cell growth, differentiation, and immune regulation. By modulating these pathways, CBD could theoretically slow the rapid skin cell turnover and calm the immune overactivation that characterize psoriasis.
Other phytocannabinoids — THC, CBG, CBN — have also shown relevant biological activities, though CBD has the most evidence. The review emphasizes that the endocannabinoid system is extensively expressed in skin tissue, making it a rational pharmacological target for dermatological conditions.
The catch: almost all evidence comes from laboratory and animal studies. Clinical trials specifically testing cannabinoids in human psoriasis patients are extremely limited.
Why it matters
Current psoriasis treatments include topical steroids (which thin the skin over time), immunosuppressants (which increase infection risk), and biologics (which are expensive and require injections). Many patients find these treatments inadequate or have significant side effects. If cannabinoid-based topicals could provide effective symptom relief with fewer side effects, they could fill an important gap — especially for mild-to-moderate psoriasis where current options are limited.
The numbers in context
Psoriasis affects 2-3% of the global population. CBD interacts with at least four receptor systems in skin (CB1, CB2, TRPV1, PPARγ). Multiple cannabinoids show anti-inflammatory and antioxidant properties in laboratory settings. Clinical trial data in human psoriasis patients is described as minimal.
How the study worked
Narrative review of published literature on phytocannabinoid effects relevant to psoriasis pathophysiology. Covered mechanisms including modulation of oxidative stress, cytokine production, keratinocyte proliferation, and immune cell function. Examined CBD, THC, CBG, CBN, and other phytocannabinoids. Reviewed relevant receptor systems (CB1, CB2, TRPV, PPAR) in skin tissue.
Who was studied
Focus on psoriasis and its treatment with phytocannabinoids.
What this study cannot tell us
Narrative review relying primarily on preclinical evidence. Almost no clinical trial data in human psoriasis patients. Laboratory findings in isolated cells and animal models often don't translate to effective treatments in humans. The skin is a complex organ with multiple cell types and immune dynamics that in vitro studies don't capture. Topical cannabinoid formulations face penetration and delivery challenges that laboratory studies bypass.
How to read the evidence
Narrative review of predominantly preclinical evidence. The biological rationale is well-supported by laboratory data, but the near-total absence of clinical trials in psoriasis patients makes the evidence preliminary.
When this study was published
Published in 2023. Topical cannabinoid products for skin conditions are an active area of both research and commercial development.
The bigger picture
This review connects the skin-focused cannabinoid research to the broader anti-inflammatory evidence reviewed in RTHC-00098 (CBD and innate immunity) and RTHC-00097 (CBG in rheumatoid arthritis). The endocannabinoid system is present throughout the body, and inflammation is a common thread — what changes is the target tissue. The same CBD mechanisms that show promise for gut inflammation (RTHC-00108) and joint inflammation may be relevant for skin conditions.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Would topical CBD or CBG creams improve psoriasis symptoms in a randomized clinical trial? What concentration and formulation of cannabinoids would be needed to achieve therapeutic levels in psoriatic skin? Could cannabinoid topicals complement existing psoriasis treatments (like topical steroids) to allow lower steroid doses? Would systemic cannabinoids (oral CBD) help severe psoriasis, or is topical application more appropriate?
Read the original research
Phytocannabinoids in the Pharmacotherapy of Psoriasis.
Molecules (Basel, Switzerland), 28(3)
Molecules is a peer-reviewed journal known for publishing research on chemistry and related fields.
Citation
Wroński, Adam; Jarocka-Karpowicz, Iwona; Stasiewicz, Anna; Skrzydlewska, Elżbieta. (2023). Phytocannabinoids in the Pharmacotherapy of Psoriasis.. Molecules (Basel, Switzerland), 28(3). https://doi.org/10.3390/molecules28031192
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk